High-Throughput Screening & Hit Discovery Services
Leading the Future of Peptide-Based Discovery
At PeptiOrigin, we leverage our innovative 3D-Structured Peptide Library and proprietary Multi-Targeting Drug Discovery (MTDD) platform to drive breakthrough drug discovery for complex diseases. Our MTDD technology enables high-efficiency screening, lead optimization, and multi-target interaction analysis, accelerating the development of next-generation therapeutics with superior efficacy and selectivity.
We specialize in High Throughput Peptide Screening to accelerate the discovery of potent and selective peptides for therapeutic applications. Our advanced High Throughput Screening Services combine innovative technologies with precise assay design to deliver reliable and reproducible results for drug discovery programs.
Multi-Targeting Peptide Drug Discovery
Leveraging our proprietary Multi-Targeting Peptide Drug Discovery (MTDD) platform and 3D-structured peptide libraries, we enable efficient exploration of complex disease targets. This approach allows for the identification of peptides with high specificity, improved stability, and desirable pharmacological profiles.
Peptide Hit Discovery
Our Peptide Hit Discovery workflow integrates molecular, enzymatic, and cell-based screening techniques:
Molecular Screening (Biacore SPR): Measure binding kinetics and affinity for precise lead identification.
Enzymatic Assays: Quantify binding, inhibition, and target engagement.
Cell-Based Screening: Validate peptide activity in disease-relevant models, including cytotoxicity, gene expression, and pathway modulation.
We use AI-driven computational modeling and high-throughput screening (HTS) to identify potent, selective multi-target drug candidates.
Proprietary Peptide Library Screening: Rapidly identifying bioactive compounds with multi-target capabilities.
Biacore SPR & Binding Kinetics Analysis: Real-time interaction studies for precise affinity measurements.
Cell-Based & Phenotypic Screening: Validating biological activity in disease-relevant models.
Our data-driven lead discovery approach accelerates the identification of high-potential multi-target drug candidates.
Our Screening Capabilities
1. Molecular Screening – Precision Analysis with Biacore SPR
We utilize Biacore Surface Plasmon Resonance (SPR) technology to deliver high-sensitivity molecular screening, ensuring accurate and real-time characterization of peptide-target interactions.
Key Capabilities of Biacore SPR Screening
Multi-Targeting Drug Discovery:
Identifying peptides which interact with several different targets.
Binding Affinity & Kinetics:
Measuring association (ka) and dissociation (kd) rates to determine equilibrium dissociation constants (KD).
Target Specificity Assessment:
Identifying off-target interactions to enhance therapeutic precision.
Concentration-Dependent Response Analysis:
Generating precise dose-response curves for lead optimization.
Real-Time Interaction Monitoring:
Obtaining kinetic and thermodynamic data without the need for labels or secondary reagents.
Structure-Activity Relationship (SAR) Studies:
Optimizing peptide properties for enhanced stability and efficacy.
With Biacore SPR, we offer label-free, real-time monitoring of biomolecular interactions, ensuring high reproducibility and sensitivity for early-stage peptide screening and lead selection.
2. Molecular Screening – Enzymatic Assays
Our enzyme-substrate binding assays provide quantitative and qualitative insights into binding affinities, dissociation kinetics, and specificity.
Enzyme Turnover & Substrate Specificity:
Profiling binding affinities and catalytic rates.
Fluorescence & FRET-Based Assays:
Detecting substrate binding and cleavage with high-sensitivity.
Competitive, Non-Competitive & Mixed Inhibition Assays:
Differentiating mechanisms of action.
Biacore SPR-Based Binding Assays:
Monitoring Label-free real-time interaction.
We specialize in enzyme inhibition profiling, enabling hit discovery and validation, structure-activity relationship (SAR) studies, and lead optimization, helping identify high-affinity enzyme modulators.
3. Cell-Based Screening – Evaluating Peptide Efficacy in Biological Systems
We employ cell-based high-throughput screening to assess peptide function in relevant biological contexts, ensuring optimal activity and minimal off-target effects.
Capabilities include
Cytotoxicity & Viability Assays:
Assessing of cell health and toxicity using MTT, LDH, and ATP-based assays.
Reporter Gene Assays:
Analyzing pathway activation and gene expression changes.
Flow Cytometry & High-Content Imaging:
Profiling cellular phenotypes and detecting biomarker.
Cell Permeability & Internalization Studies:
Evaluating compound uptake and intracellular localization.
Receptor-Ligand Binding Assays:
Investigating molecular interactions between receptors and ligands.
Our custom assay development ensures that each screening campaign is tailored to the unique needs of your therapeutic or cosmetic peptide program.
Frequently Asked Questions (FAQs)
Q: What compound libraries does Charles River use for high-throughput screening assay development?
A: We utilize Biacore Surface Plasmon Resonance (SPR) technology to deliver high-sensitivity molecular screening, ensuring accurate and real-time characterization of peptide-target interactions.
Other Services
Contact
We value your inquiries and feedback! Whether you’re looking for more information about our peptide library, services, or collaboration opportunities, our team is here to assist you.
中文 
